Affordable Access

Publisher Website

Suppression by spironolactone of 7,12-dimethylbenz(a)anthracene-induced mammary tumors

Authors
Journal
European Journal of Cancer (1965)
0014-2964
Publisher
Elsevier
Publication Date
Volume
6
Issue
3
Identifiers
DOI: 10.1016/0014-2964(70)90022-8
Disciplines
  • Biology

Abstract

Abstract Pretreatment with spironolactone, an antimineralocorticoid steroid lactone, delays the development and decreases the incidence and yield of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in rats. The mechanism of this suppressive action is not fully understood but on the basis of some recent findings it seems reasonable to suppose that spironolactone is capable of influencing the intermediary metabolism of DMBA by inducing or stimulating microsomal enzymes in the hepatocytes which convert the carcinogen into inactive derivatives. Direct evidence is still lacking but the problem warrants further study primarily because spironolactone, in contrast to the other microsomal enzyme inducers, is a non-toxic compound which can be administered for a considerable length of time without serious consequences.

There are no comments yet on this publication. Be the first to share your thoughts.